Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin
- PMID: 2127345
- PMCID: PMC172014
- DOI: 10.1128/AAC.34.11.2142
Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin
Abstract
Selection and regrowth of ciprofloxacin-resistant variants, which were present in low frequencies in the initial inoculum, were seen when large inocula of Pseudomonas aeruginosa were incubated with ciprofloxacin. These variants showed cross resistance to other quinolones. In 8 of 13 strains tested, ciprofloxacin selected imipenem-resistant variants in a similar way to imipenem. The opposite phenomenon of ciprofloxacin-imipenem cross resistance after exposure to imipenem was not detected. None of the ciprofloxacin-resistant variants showed cross resistance to aztreonam, piperacillin, or tobramycin. These findings indicate that widespread and uncritical use of ciprofloxacin gives a potential risk of development of resistance in P. aeruginosa not only to quinolones but also to another unrelated useful agent, imipenem. In vitro evaluation of this phenomenon in isolates from patients with P. aeruginosa infections may be justified, since strains differ in development of quinolone-imipenem cross resistance after ciprofloxacin exposure.
Similar articles
-
Cross-resistance of Pseudomonas aeruginosa to ciprofloxacin, extended-spectrum beta-lactams, and aminoglycosides and susceptibility to antibiotic combinations.Antimicrob Agents Chemother. 1989 Aug;33(8):1368-72. doi: 10.1128/AAC.33.8.1368. Antimicrob Agents Chemother. 1989. PMID: 2508546 Free PMC article.
-
Subpopulations of variants resistant to imipenem in Pseudomonas aeruginosa.J Antimicrob Chemother. 1988 Nov;22(5):643-9. doi: 10.1093/jac/22.5.643. J Antimicrob Chemother. 1988. PMID: 3145266
-
Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy.J Antimicrob Chemother. 1992 Mar;29(3):307-12. doi: 10.1093/jac/29.3.307. J Antimicrob Chemother. 1992. PMID: 1317371
-
In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.J Chemother. 1996 Oct;8(5):358-64. doi: 10.1179/joc.1996.8.5.358. J Chemother. 1996. PMID: 8957715
-
Recent advancements and perspective of ciprofloxacin-based antimicrobial polymers.J Biomater Sci Polym Ed. 2023 May;34(7):918-949. doi: 10.1080/09205063.2022.2145872. Epub 2022 Nov 16. J Biomater Sci Polym Ed. 2023. PMID: 36346071 Review.
Cited by
-
Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.Drugs. 1996 Jun;51(6):1019-74. doi: 10.2165/00003495-199651060-00010. Drugs. 1996. PMID: 8736621 Review.
-
Role of mutations in DNA gyrase genes in ciprofloxacin resistance of Pseudomonas aeruginosa susceptible or resistant to imipenem.Antimicrob Agents Chemother. 1995 Oct;39(10):2248-52. doi: 10.1128/AAC.39.10.2248. Antimicrob Agents Chemother. 1995. PMID: 8619577 Free PMC article.
-
Optimal use of antibiotics for intubation-associated pneumonia.Intensive Care Med. 2001 Feb;27(2):337-9. doi: 10.1007/s001340000755. Intensive Care Med. 2001. PMID: 11396275 No abstract available.
-
Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.Clin Infect Dis. 2019 May 30;68(12):2045-2052. doi: 10.1093/cid/ciy825. Clin Infect Dis. 2019. PMID: 30256922 Free PMC article.
-
Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression.Antimicrob Agents Chemother. 1996 Sep;40(9):2021-8. doi: 10.1128/AAC.40.9.2021. Antimicrob Agents Chemother. 1996. PMID: 8878574 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources